OXB to present at the Leerink Partners Global Healthcare Conference
OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and ...
牛津生物医药支持创新性囊性纤维化基因疗法临床试验
此次试验将评估吸入型慢病毒载体基因疗法BI 3720931的疗效。这种创新疗法通过将功能性CFTR基因直接插入气道上皮细胞的DNA中，有望满足10-15%由于特定突变或对现有CFTR调节剂产生耐受性的囊性纤维化患者的需求。
London South East7 天
Oxford Biomedica Share Chat (OXB)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
thebusinessmagazine10 天
Revenues up 44 per cent at OXB as biotech’s pivot pays off
OXB (formerly Oxford Biomedica) expects to report revenues of between £127 million and £129 million for the year ended 31 ...
GlobalData on MSN7 天
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
Morningstar22 天
Oxford BioMedica PLC OXB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...